A platform for post-translational spatiotemporal control of cellular proteins

Brianna Jayanthi¹,†, Bhagyashree Bachhav²,†, Zengyi Wan³, Santiago Martinez Legaspi², Laura Segatori¹,²,³,⁴,*

¹Systems, Synthetic and Physical Biology Graduate Program, Rice University, Houston, Texas 77005, USA.
²Department of Chemical and Biomolecular Engineering, Rice University, Houston, Texas 77005, USA.
³Department of Bioengineering, Rice University, Houston, Texas 77005, USA.
⁴Department of Biosciences, Rice University, Houston, Texas 77005, USA.

*Corresponding author: Tel:+1 713 348 3536; E-mail: segatori@rice.edu
†These authors contributed equally to this work.
ABSTRACT

Mammalian cells process information through coordinated spatiotemporal regulation of proteins. Engineering cellular networks thus relies on efficient tools for regulating protein levels in specific subcellular compartments. To address the need to manipulate the extent and dynamics of protein localization, we developed a platform technology for target-specific control of protein destination. This platform is based on bifunctional molecules comprising a target-specific nanobody and universal sequences determining target subcellular localization or degradation rate. We demonstrate that nanobody-mediated localization depends on the expression level of the target and the nanobody, and the extent of target subcellular localization can be regulated by combining multiple target-specific nanobodies with distinct localization or degradation sequences. We also show that this platform for nanobody-mediated target localization and degradation can be regulated transcriptionally and integrated within orthogonal genetic circuits to achieve the desired temporal control over spatial regulation of target proteins. The platform reported in this study provides an innovative tool to control protein subcellular localization which will be useful to investigate protein function and regulate large synthetic gene circuits.

Keywords: degradation / localization / mammalian genetic circuits / nanobody / orthogonal protein regulation
INTRODUCTION

Cellular information processing is primarily managed by regulating protein concentration in space and time (1, 2). Temporal regulation of protein concentration is mostly achieved through activation of transcription factors and protein degradation, which are controlled through a myriad of well-studied mechanisms (3–12). Proteins are typically synthesized in the cytosol or on ER-bound ribosomes and trafficked to their final destination based on signal sequences contained in the protein’s primary sequence (13). Protein function depends on subcellular location and is drastically affected by environmental conditions, such as pH and redox state (14–17). Protein localization also dictates the availability of interacting proteins (18–21) and substrates (22–24), further diversifying protein functionality. Moreover, many cellular responses are regulated by mechanisms controlling changes in localized protein concentration, including translocation of transcription factors from the cytosol to the nucleus (25), release of mitochondrial proteins into the cytosol during apoptosis (26), endocytic recycling of plasma membrane proteins (27), and scaffold recruitment and release of signaling pathway components (28). Spatial organization of cellular components is also of vital importance in cellular manufacturing of proteins and metabolites (29), as it provides a mechanism for accelerating reactions (30, 31) and reducing interference between pathways with shared components (32). Furthermore, aberrant localization of proteins has been associated with disease states including neurodegeneration (33–35), metabolic impairment (36, 37) and cancer (38, 39). Controlling protein localization would thus open the way to a number of applications ranging from fundamental studies of protein function to therapeutic protein delivery. Previous attempts to target proteins to
specific compartments have facilitated characterization studies (40), manipulation of protein activity (41, 42), and control of metabolic pathways (43, 44). Perturbing cellular protein levels and monitoring the associated phenotypic changes is widely recognized as a powerful approach to investigate biological pathways (45–47). Similarly, characterization of the physiological role of protein localization in the complex milieu of mammalian cells depends on tools to precisely perturb the location of cellular proteins and monitor the associated phenotypic changes (48–50).

Control of protein localization can be achieved through fusion of a protein of interest to well-characterized sequences known to control protein trafficking (13, 51). This approach, however, requires genetic manipulations of the target protein, which may potentially affect the protein’s native function (52, 53). In addition, the efficiency of protein localization is largely target-specific (54, 55). Control over the location of a target protein can also be achieved through engineered inducible interactions between a protein residing at the location of interest and the target protein. This approach to regulate protein localization requires extensive genetic manipulation and is generally implemented through fusion of a dimerizing domain to a protein at the desired location and to the target protein. Small molecule (40, 41, 56–58) or light (59–61) inducible dimerization has been widely used to control target localization. These systems, however, are limited by the requirement for a binding partner with the correct subcellular address and that is amenable to protein engineering. Moreover, regulating localization of proteins based on fusion to a signal sequence or dimerization domain is a cumbersome endeavor due to the need to modify each target individually. Furthermore, the availability of a restricted number of inducible dimerization domains (56) limits the
development of strategies for directing single targets to multiple compartments or for multiplexing control of targets. An alternative approach to control location of cellular proteins relies on the use of binding proteins (DARPins, antibody fragments, and nanobodies) functionalized with localization signals (50, 62–64). While target-specific recognition molecules engineered to control target localization provide powerful tools to investigate the role of protein subcellular localization without modifying the target protein, current approaches based on recognition molecule-mediated localization do not allow for user-defined control over the extent and dynamics of target localization.

In this study, we addressed the need for a platform technology for regulating the localization of cellular proteins that can be potentially adapted to any cellular target protein, provides dynamic control of the protein levels at the desired subcellular location, and allows modulating subcellular localization of a single target to multiple compartments. In this regard, we constructed a nanobody-based platform for tunable control of target protein localization. Specifically, we built a toolbox of GFP-specific nanobodies functionalized to direct a target to a series of subcellular compartments (NanoLoc). We demonstrated that nanobody-mediated localization of a target protein depends on the expression level of the nanobody and of the target protein. We also provided proof-of-principle demonstration of a universal NanoLoc targeting a peptide tag (BC2) (65) for controlling the function of a BC2-tagged transcription factor via targeted localization. We developed a method to modulate the extent of target subcellular localization based on combining the use of target-specific nanobodies mediating localization (VHH_{Loc}) and degradation (VHH_{Deg}) (66). Finally, we interfaced this toolkit
for nanobody-mediated control with different strategies for transcriptional regulation of the nanobody to achieve spatial and temporal control of the target protein.

MATERIALS AND METHODS

Plasmids and Cloning: Localization signal sequences are listed in Supplementary Table 1. The plasmids and primers used in this study are listed in Supplementary Table 2 and Supplementary Table 3, respectively. Plasmids were transformed and maintained in Stbl3 E. Coli competent cells (Thermo Fisher Scientific). PCR amplifications of DNA fragments were performed using Kappa HiFi DNA polymerase (Kapa Biosystems) according to the manufacturer’s protocol. Plasmid sequences are available in the online supplementary information.

The plasmid pSV40-GFP was generated by replacing the CMV promoter of pLenti CMV GFP Blast (Addgene plasmid # 17445) with the SV40 promoter using restriction enzymes ClaI and BamHI. The neomycin-resistance gene was PCR amplified from pcDNA3.1+ (Invitrogen) with primers designed to add BamHI and BlpI enzyme recognition sites 5’ and 3’, respectively. The resulting fragment was ligated into the pLenti SV40 GFP vector, replacing the blasticidin-resistance gene, after digestion with BamHI and BlpI restriction enzymes.

The GFP-specific VHH encoding sequence with a 5’ fused HA tag sequence was amplified from pvhh (66). The pCMV-VHH\textsubscript{MOM}, pCMV-VHH\textsubscript{ERM}, pCMV-VHH\textsubscript{PEX}, and pCMV-VHH\textsubscript{NLS} were constructed using overlap extension PCR to fuse the localization signal sequence 3’ of the HA-VHH encoding sequence. The PCR amplified fragments encoding HA-VHH\textsubscript{Loc} variants were ligated into the pvhh vector (66) after digestion with
KpnI and NotI restriction enzymes. To generate pCMV-VHH<sub>PM</sub>, the sequence encoding the plasma membrane localization signal was fused to the 5' end of the <i>vhh</i> and the HA tag encoding sequence was fused to the 3' end of the <i>vhh</i> using overlap extension PCR. The resulting sequence was ligated into the pyvh<sub>H</sub> vector after digestion with AflII and NotI restriction enzymes.

The sequence encoding the BC2 tag (65) was obtained from Integrated DNA technologies and PCR amplified with primers designed to add NotI and XhoI enzyme recognition sites 5' and 3', respectively. The resulting fragment was ligated into the pCMV-TetR vector (Invitrogen) after digestion with NotI and XhoI restriction enzymes, generating the plasmid pCMV-TetR-BC2T. The <i>irfp</i> sequence was PCR amplified from piRFP (Addgene plasmid #31857) with primers designed to add Nhel and NotI enzyme recognition sites 5' and 3', respectively. The pCMV-iRFP-BC2T plasmid was generated from pCMV-TetR-BC2T by replacing <i>tetR</i> with <i>irfp</i> using Nhel and NotI restriction enzymes. The <i>tTA</i> sequence was PCR amplified from ptTA (67) with primers designed to add Nhel and NotI enzyme recognition sites 5' and 3', respectively. The pCMV-tTA-BC2T plasmid was generated from pCMV-iRFP-BC2T by replacing <i>irfp</i> with <i>tTA</i> using Nhel and NotI restriction enzymes. The sequence encoding BC2 tag-specific VHH (65) with a 5' HA tag fusion was obtained from Integrated DNA technologies. The resulting sequence (VHH<sub>BC2T</sub>) was PCR amplified with primers designed to add KpnI and Bpl restriction sites at the 5' and 3', respectively. The pCMV-VHH<sub>BC2T</sub><sup>BC2T</sup> was constructed by excising the VHH<sub>NLS</sub> sequence from the pCMV-VHH<sub>NLS</sub> and replacing it with VHH<sub>BC2T</sub>, using restriction enzymes KpnI and Bpl.
The pCMV-TetR-IRES-EKRAB plasmid was constructed by ligating TetR (Invitrogen), an IRES (Addgene Plasmid #21547) and EKRAB (68) into the pLenti CMV eGFP Zeo vector (Addgene Plasmid #17449) after restriction enzyme digestion of TetR with SpeI and SbfI, IRES with SbfI and MluI, and EKRAB with MluI and SalI.

The pCMV/TO-iRFP plasmid was generated from pcDNA4/TO (Invitrogen) by replacing gfp with irfp (piRFP, Addgene plasmid #31857) using KpnI and NotI restriction enzymes. The CMV promoter containing four downstream repeats of the ETR operator site (68) (CMV/ETR) was generated by assembly PCR. The CMV/ETR promoter sequence was ligated into the pCMV/TO-iRFP vector, replacing the CMV/TO promoter, after digestion with MluI and KpnI restriction enzymes. The pCMV/TO-VHH\textsubscript{MOM} plasmid was constructed by excising the HA-VHH\textsubscript{MOM} sequence from pCMV-VHH\textsubscript{MOM} and ligating it into pCMV/TO-iRFP, replacing irfp, using restriction enzymes KpnI and NotI. The pCMV/TO-VHH\textsubscript{NLS} plasmid was constructed in the same manner by excising VHH\textsubscript{NLS} from pCMV-VHH\textsubscript{NLS}. The pCMV/ETR.VHH\textsubscript{ODC(wt)} plasmid was constructed by excising VHH\textsubscript{ODC(wt)} from pvhh-ODC (66) and ligating it into the pCMV/ETR-iRFP backbone, replacing irfp, using restriction enzymes KpnI and NotI. The pCMV/ETR-VHH\textsubscript{MOM} plasmid was constructed in the same manner by excising VHH\textsubscript{MOM} from pCMV-VHH\textsubscript{MOM}.

To construct pCMV/ETR-VHH\textsubscript{NLS}-IRES-PIPKRAB, the insert sequence encoding HA-VHH\textsubscript{NLS}-IRES-PIPKRAB was generated by PCR amplification of HA-VHH\textsubscript{NLS} from pCMV-VHH\textsubscript{NLS} with primers designed to add the NheI and Agel enzyme recognition sites at the 5’ and 3’ ends, respectively. The IRES sequence was amplified from pCMV-TetR-IRES-EKRAB with primers designed to add the Agel and AflII enzyme recognition
sites at the 5' and 3' ends, respectively, and the PIPKRAB sequence (69) was amplified with primers designed to add the AflII and NotI enzyme recognition sites at the 5' and 3' ends, respectively. These three insert sequences were then ligated into the pCMV/ETR-iRFP backbone, replacing irfp, using NheI and NotI restriction enzymes.

The pCMV/PIR-VH\textsubscript{MOM}-IRES-EKRAB plasmid was constructed by first replacing the ETR operator sites of pCMV/ETR-iRFP with PIR operator sites generated by assembly PCR (69) to yield pCMV/PIR-iRFP. The sequence encoding VHH\textsubscript{MOM} was PCR amplified from pCMV-VH\textsubscript{MOM} with overlapping primers designed to add a FLAG tag encoding sequence and a KasI enzyme recognition site at the 5' end and the AgeI enzyme recognition site at the 3' end. The IRES-EKRAB sequence was PCR amplified from pCMV.TetR-IRES-EKRAB with primers designed to add the AgeI and NotI enzyme recognition sites at the 5' and 3' ends, respectively. The FLAG-VH\textsubscript{MOM} and IRES-EKRAB inserts were then ligated into the pCMV/PIR-iRFP backbone, replacing irfp, using KasI and NotI restriction enzymes.

**Cell culture and transfections:** HEK293 cells (ATCC) and HEK293T cells (ATCC) were cultured in DMEM/High glucose (Hyclone) supplemented with 10% fetal bovine serum (FBS, GenClone) and 1% penicillin–streptomycin–glutamine (PSQ, Hyclone) and maintained at 37 °C and 5% CO\textsubscript{2}. Cells were passaged using PBS (Lonza) and trypsin (TrypLE, GIBCO Invitrogen).

Transient transfections were performed by seeding cells onto 24-well plates, 12-well plates or 10 cm tissue culture dishes. After 24 h, cells were transfected using JetPrime (Polyplus transfection) according to manufacturer's protocol. The medium was replaced
with fresh medium 8 h or 16 h post-transfection and cells were re-plated onto coverslips 48 h post-transfection at a density of 18 x 10^4 cells/mL. Cells were fixed for analysis at 72 h post-transfection unless otherwise indicated.

**Lentivirus production and transduction:** Third-generation lentiviruses were generated by seeding HEK293T cells onto 10 cm tissue culture dishes at a density of 10 x 10^4 cells/mL. Cells were transfected with pSV40-GFP or pCMV-TetR-IRES-EKRAB, and the packaging plasmids pMLg/PRRE (Addgene plasmid #12251), pRSV-Rev (Addgene plasmid #12253), and pMD2.g (Addgene plasmid # 12259) in a 2:5:2:5:3 ratio, respectively. The medium was replaced with fresh medium 8 h post-transfection and the virus-containing medium was collected after 48 h. The virus was concentrated using a Lenti-X concentrator (Clontech) according to manufacturer’s protocol.

Cell transductions were conducted by seeding HEK293 cells onto 12-well plates at a density of 10 x 10^4 cells/mL. After 24 h, the medium was replaced with medium supplemented with virus particles and 8 μg/mL polybrene. The medium supplemented with virus was replaced with fresh medium 24 h post-transduction.

**Generation of stable cell lines.** To generate the GFP stable cell lines (HEK293/GFP#1, HEK293/GFP#2 and HEK293/GFP#3), HEK293 cells were seeded onto 12-well plates and transduced with pSV40-GFP. Cells were transferred into 10 cm tissue culture dishes 48 h post-transduction and selected for 2 weeks using 1 mg/mL geneticin (MilliporeSigma). Cells were analyzed with a Nanocellect (Wolf) to sort cells presenting different levels of GFP fluorescence. Sorted cells were seeded onto 96-well
plates containing DMEM with 20% FBS at a density of 1 cell/well, expanded, and monoclonal cell populations analyzed by flow cytometry to select the three cell lines presenting different levels of GFP fluorescence used in this study.

To generate the dual-input stable cell line (HEK293/GFP2R), HEK293/GFP#1 cells were seeded onto 12-well plates and transduced with pCMV-TetR-IRES-EKRAB. Cells were transferred into 10 cm tissue culture dishes 48 h post-transduction and selected for 2 weeks using 500 µg/mL Zeocin (InvivoGen). The selected polyclonal population was diluted onto 96-well plates at a concentration of 0.5 cells/well and expanded. Monoclonal populations were then screened by transfection with pCMV/ETR-iRFP and pCMV/TO-iRFP and treated with Em and Tc. The iRFP fluorescence of cells treated with or without inducer was measured by flow cytometry. The cell population exhibiting the greatest range of iRFP fluorescence intensity upon treatment with both Em and Tc was selected for further experiments.

**Flow cytometry analyses.** Cell were analyzed with a FACSCanto II flow cytometer (BD Biosciences). GFP fluorescence intensity was detected using a 488 nm laser and 530/30 nm emission filter. iRFP fluorescence intensity was detected using a 635 nm laser and 780/60 nm emission filter. At least 10,000 cell events were recorded in each sample for analysis.

**Immunofluorescence for confocal microscopy.** Cells were seeded onto coverslips in a 24-well plate at a density of 9 x 10⁴ cells. To stain mitochondria and plasma membrane, samples were stained with MitoTracker dye (200nM, ThermoFisher)...
or Membrite dye (Biotium) prior to fixing 24 h post-seeding according to the manufacturer’s protocol. Cells were then washed once with PBS, fixed with 4% paraformaldehyde (15 min), and permeabilized with 0.1% TritonX-100 (7 mins). Cells were then washed three times with 0.1% Tween-20 in PBS (PBST) and blocked with 8% BSA (Calbiochem, 2930) for 1 h. Cells were washed three times with PBST and incubated in primary antibody (rabbit anti-HA SantaCruz Biotechnology sc-805, 1:250; mouse anti-calnexin, ThermoFisher MA3-027, 1:50; mouse anti-PMP70, Novus Biologicals NBP2-36770, 1:50) overnight. Cells were then washed three times with PBST and incubated with appropriate secondary antibodies (goat anti-rabbit DyLight 549 conjugated, Rockland 611-142-002, 1:500; goat anti-rabbit DyLight 405 conjugated, Rockland 611-146-002, 1:200; goat anti-mouse DyLight 549 conjugated, KPL 072-04-18-06, 1:500) for 2 h. Hoechst 3342 nuclear stain (Thermo Fisher Scientific) was added along with secondary antibodies where indicated. Coverslips were mounted onto glass slides using anti-fade solution (Invitrogen, S36936). Images were obtained with a Nikon A-1 confocal microscope (Nikon) and the Nikon NIS Element C imaging software. The acquired images were minimally processed using ImageJ software to adjust brightness and contrast where indicated (70).

**Image analysis.** Analyses of GFP fluorescence intensity in 8-bit images was conducted using ImageJ. The areas of interest (cell and compartment) were segmented by establishing a threshold based on pixel intensity in the appropriate color channel for each image. The area of interest corresponding to the cell was first segmented in the color channel showing iRFP fluorescence, and then the area of interest corresponding
to the subcellular compartment was further segmented within the cell area of interest in the color channel corresponding to the compartment stain. The fluorescence intensity was quantified by calculating the mean pixel intensity within the segmented subcellular compartment area of interest in the color channel showing GFP fluorescence. At least 15 cells per sample were analyzed. ImageJ macros are available at https://github.com/SegatoriLab/NanoLoc.

**Statistical analysis.** All data are reported as mean and error bars represent the standard error of at least three independent experiments. Statistical significance between samples was calculated using an unpaired two-tailed Student’s $t$-test.

**RESULTS**

**Design of a nanobody-based platform for spatial control of GFP.**

We aimed to build a platform technology for controlling protein subcellular localization that could be adapted to target potentially any cellular protein to any cellular compartment. As a proof-of-principle demonstration, we built a set of GFP-specific nanobody (VHH) (71) variants fused to different localization signals, namely the mitochondrial outer membrane anchor (VHH$_{MOM}$) (72), the endoplasmic reticulum membrane anchor (VHH$_{ERM}$) (73), the peroxisome targeting signal (VHH$_{PEX}$) (74), the plasma membrane anchor (VHH$_{PM}$) (75), and the nuclear localization signal (VHH$_{NLS}$) (76) (Supplementary Fig. 1, Supplementary Table 1). All nanobody variants (VHH$_{Loc}$) contained the HA tag for detection. Specifically, the mitochondrial outer membrane anchor is a 39 amino acid C-terminal transmembrane segment of the OMP25 protein.
that mediates protein localization to the mitochondrial outer membrane (72, 77); the endoplasmic reticulum targeting signal is a C-terminal segment of the protein tyrosine phosphate (PTP1B), which contains a single stretch transmembrane domain and undergoes post-translational attachment to the ER membrane network (73); the peroxisome targeting signal is a C-terminal dodecamer that interacts with the tetratricopeptide repeat domain of PEX5 receptor and initializes a peroxisomal translocation event via interaction with the PEX5 proteins (74); the plasma membrane anchor consists of a sequence encoding the first 15 amino acids of Gnai2 (G Protein Subunit Alpha I2) containing N-myristol and S-palmitoyl motifs that mediates protein localization to the plasma membrane (75); and the nuclear localization signal is a seven amino acid sequence derived from the SV40 large T antigen that promotes nuclear transport of otherwise cytoplasmic proteins (76).

To verify that the resulting VHH\textsubscript{Loc} variants localize cytosolic GFP to the corresponding subcellular compartments, we analyzed the colocalization of VHH\textsubscript{Loc}, GFP, and the subcellular compartment designated by the localization tag. Specifically, HEK293 cells stably expressing GFP (HEK293/GFP#1) were transiently transfected for the expression of the VHH\textsubscript{Loc} variants to evaluate GFP localization due to the VHH\textsubscript{Loc} as dictated by the localization signal. Cells were analyzed by confocal microscopy for detection of GFP, VHH (anti-HA), and the subcellular compartments, namely the mitochondria (MitoTracker stain), endoplasmic reticulum membrane (anti-CANX), peroxisome (anti-PMP70), plasma membrane (MemBrite stain), or nucleus (Hoechst stain). Imaging analyses revealed a distinct GFP and VHH distribution pattern in cells transfected for the expression of each VHH\textsubscript{Loc}. Specifically, the VHH\textsubscript{Loc} signal was found.
to colocalize with the subcellular compartment marker, indicating that the localization signal controls the VHH subcellular localization (Fig. 1, merged compartment-VHH, purple). GFP and VHH\textsubscript{Loc} signals also colocalized, suggesting formation of the GFP-VHH complex (Fig. 1, merged GFP-VHH, cyan). Finally, colocalization of GFP and the subcellular compartment marker indicates that VHH\textsubscript{Loc} controls GFP localization (Fig. 1, merged compartment-GFP, yellow). Cells transfected with a control plasmid lacking the gene encoding the nanobody display a diffuse GFP signal that does not colocalize with the fluorescent signal of any of the compartment markers (Supplementary Fig. 2), confirming that VHH\textsubscript{Loc} controls GFP localization to the compartment designated by the localization signal.

To test the residence time of GFP within each subcellular compartment, we monitored GFP fluorescence over time in cells expressing the VHH\textsubscript{Loc} variants. HEK293/GFP#1 cells stably expressing the erythromycin-dependent transrepressor (EKRAB) (68) were transiently transfected for the expression of each VHH\textsubscript{Loc} under the control of the erythromycin-inducible operator, and treated with erythromycin (Em) to induce expression of VHH\textsubscript{Loc} (Fig. 2A). Confocal microscopy analyses were initiated at the time of removal of Em from the culturing medium. Localization of GFP to the ER membrane and plasma membrane decayed rapidly with complete loss of localization by 48 h and 72 h, respectively. Nuclear localization of GFP appeared stable for the first 72 h, followed by a slow decay and complete loss of localization by 120 h. Peroxisomal and mitochondrial localization presented similar temporal patterns resulting in total loss of localization by 144 h (Fig. 2B). These results are indicative of a compartment-specific
localization decay rate, which may be due to a multitude of factors including different compartment turnover rates and localization mechanisms.

To test whether GFP can be simultaneously targeted to multiple subcellular compartments, HEK293/GFP#1 cells were co-transfected for the expression of two VHH_{Loc} variants fused to different localization signals. Expression of a single VHH_{Loc} displayed the pattern of GFP fluorescence consistent with GFP localization to the designated compartment (Fig. 3A). Expression of two distinct VHH_{Loc}, however, resulted in a pattern of GFP fluorescence consistent with GFP localization in two distinct compartments for all combinations of VHH_{Loc} tested (Fig. 3B). These results indicate that a cytosolic protein can be localized simultaneously to multiple subcellular compartments through co-expression of the appropriate VHH_{Loc} variants.

To test the extent to which the VHH_{Loc} expression level affects GFP localization, we monitored GFP localization within a representative subcellular compartment (mitochondria) upon modulation of the corresponding VHH_{Loc} variant (VHH_{MOM}) expression level. Specifically, HEK293/GFP#1 cells were transiently transfected with varying amounts of VHH_{MOM} expressing plasmid (10 - 450 ng) and the extent of colocalization of GFP and MitoTracker stain quantified as a function of plasmid amount. Transfected cells were selected and analyzed based on expression of the transfection control (iRFP). The GFP signal of transfected cells was quantified (78). Localization of GFP to the mitochondria was found to depend on VHH_{MOM} expression level until a saturation point. Specifically, the extent of mitochondria-localized GFP in HEK293/GFP#1 cells increased exponentially (20 - 150 ng of plasmid) until a 16.5-fold maximum compared to cells not expressing VHH_{MOM} and plateaued upon transfection.
with higher amounts of \( \text{VHH}_{\text{MOM}} \) expressing plasmid (Fig. 4A and Supplementary Fig. 3A). The amount of cytoplasmic GFP was found not to vary dramatically under these conditions.

To further characterize \( \text{VHH}_{\text{Loc}} \)-mediated localization, we investigated the effect of GFP expression level on GFP localization by quantifying mitochondria-localized GFP fluorescence in cells presenting different GFP expression levels. We used three stable HEK293 cell lines expressing different GFP levels, namely HEK293/GFP#1 (low), HEK293/GFP#2 (intermediate), and HEK293/GFP#3 (high). Specifically, HEK293/GFP#2 cells displayed a 6.3-fold increase in total GFP fluorescence signal compared to HEK293/GFP#1 cells and HEK293/GFP#3 cells displayed a 15.4-fold increase compared to HEK293/GFP#1 cells (Supplementary Fig. 3B). These stable GFP-expressing cell lines were transiently transfected with the amount of \( \text{VHH}_{\text{MOM}} \) expressing plasmid (450 ng, Fig. 4A) expected to maximize GFP localization. Transfected cells were analyzed by confocal microscopy to evaluate the amount of cytoplasmic GFP and the extent of GFP localization to the mitochondria (Fig. 4B).

These analyses revealed that GFP localization to the mitochondria depends on the total level of GFP. Specifically, mitochondria-localized GFP fluorescence of HEK293/GFP#2 and HEK293/GFP#3 cells was 2.8-fold and 6.7-fold compared to that of HEK293/GFP#1 cells reflecting the differences in total GFP levels (Fig. 4B).

These results, taken together, demonstrate that the extent of localization of a cytosolic target protein to a specific subcellular compartment can be tuned using the NanoLoc platform by modulating the expression level of the \( \text{VHH}_{\text{Loc}} \) variant relative to the expression level of the target protein.
To explore the functional effect of VHH\textsubscript{Loc}-mediated localization, we tested the use of the NanoLoc system to control the function of the tetracycline transactivator (tTA) (79). Because expression of a target gene under control of the tTA-inducible promoter depends on tTA nuclear localization, we explored the functional effect of VHH\textsubscript{Loc}-mediated localization by monitoring the expression of a reporter gene upon co-expression of a tTA-targeting VHH fused to a nuclear localization signal (VHH\textsubscript{NLS}). VHH\textsubscript{Loc}-mediated tTA localization was achieved using a tTA variant fused to the BC2 tag and a nanobody against the BC2 peptide tag (65) fused to the nuclear localization signal. VHH\textsubscript{Loc}-mediated tTA localization was compared to tTA nuclear localization achieved through expression of a tTA variant directly fused to a nuclear localization signal (80, 81). HEK293 cells were transfected with a plasmid encoding GFP under control of a cassette comprising 7 tetracycline operator repeats and the CMV promoter (79). The resulting cells were transfected with a plasmid encoding tTA fused to the BC2 tag (tTA-BC2T) and the BC2 tag-specific nanobody fused to the nuclear localization signal (VHH\textsubscript{BC2T \textsubscript{NLS}}) or with a plasmid encoding tTA fused to the nuclear localization signal (tTA-NLS). Cells transfected for the expression tTA-NLS presented an 8-fold increase in GFP fluorescence compared to control cells lacking tTA (Fig. 5). Cells expressing tTA fused to the peptide tag (without any means of controlling tTA nuclear localization) presented about 50% of the GFP fluorescence signal detected in cells expressing tTA-NLS. Expression of the tag-specific nuclear NanoLoc (VHH\textsubscript{BC2T \textsubscript{NLS}}) restored GFP expression to a level comparable to that obtained in cells expressing the tTA-NLS (Fig. 5). In addition to demonstrating the use of the NanoLoc to control localization-
dependent protein function, these results also validate the use of the NanoLoc for controlling the localization of different types of target proteins.

To investigate whether the extent of target protein subcellular localization could be further modulated post-translationally by controlling the target protein degradation rate, we combined nanobody-mediated modulation of GFP subcellular localization and degradation rate. GFP degradation rate was controlled using the previously developed NanoDeg platform consisting of target-specific nanobody variants fused to a degradation tag (VHH\textsubscript{Deg}) (66). Target localization (VHH\textsubscript{Loc}) and degradation (VHH\textsubscript{Deg}) were achieved using the same nanobody to ensure nanobody binding with the same affinity. HEK293/GFP#1 cells were transiently transfected for the expression of VHH\textsubscript{MOM} and varying amounts of a VHH\textsubscript{Deg} variant containing the 37 amino acid carboxy-terminal sequence of ornithine decarboxylase (VHH\textsubscript{ODC}) (82). Transfected cells were analyzed by confocal microscopy to quantify mitochondria-localized GFP fluorescence. Co-expression of VHH\textsubscript{MOM} and VHH\textsubscript{ODC} resulted in a reduction of mitochondria-localized GFP fluorescence compared to control cells lacking VHH\textsubscript{ODC} which was proportional to the amount of VHH\textsubscript{ODC}-encoding plasmid (Fig. 6A). Localized GFP fluorescence was reduced by 66%, 81%, and 92% in cells expressing VHH\textsubscript{MOM} to VHH\textsubscript{ODC} ratios of 1:0.5, 1:2 and 1:3, respectively, compared to control cells (Fig. 6B), indicating that the GFP levels in the compartment specified by the VHH\textsubscript{Loc} can be controlled by modulating the expression of VHH\textsubscript{Deg}.

To investigate whether GFP subcellular localization could be further tuned by modulating the VHH\textsubscript{Deg} degradation rate, rather than its expression level, we tested GFP localization upon expression of VHH\textsubscript{ODC} variants presenting different half-lives. We
used a set of VHH\textsubscript{ODC} variants containing mutations in the ODC tag (83) that alter
VHH\textsubscript{ODC} half-life (66), namely VHH\textsubscript{ODC(T15A)}, VHH\textsubscript{ODC}, and VHH\textsubscript{ODC(D12A)}, which were
reported to present half-lives of 2.1 h, 1.3 h, and 0.9 h, respectively (66).

HEK293/GFP#1 cells were transiently transfected for the expression of VHH\textsubscript{MOM} and
VHH\textsubscript{ODC(T15A)}, VHH\textsubscript{ODC}, or VHH\textsubscript{ODC(D12A)} and analyzed by confocal microscopy to quantify
mitochondria-localized GFP fluorescence. Imaging analyses revealed a reduction in
mitochondria-localized GFP fluorescence compared to control cells that was
proportional to the VHH\textsubscript{ODC} variant half-life. Localized GFP fluorescence was reduced
by 67%, 80%, and 87% in cells expressing VHH\textsubscript{ODC(T15A)}, VHH\textsubscript{ODC}, and VHH\textsubscript{ODC(D12A)},
respectively, compared to control cells (Figs. 6C-D), indicating that GFP levels in the
compartment specified by the VHH\textsubscript{Loc} can be controlled by modulating the half-life of
VHH\textsubscript{Deg}.

These results support the development of an integrated framework based on the
NanoLoc and NanoDeg platforms for modulating target protein concentration in specific
subcellular compartments by tuning nanobody-mediated target localization and
nanobody-mediated target degradation.

**Tuning GFP localization by modulating nanobody-mediated control of GFP**

localization and degradation.

To investigate strategies to use the NanoLoc and NanoDeg platforms for achieving
temporal control of the target protein localization, we built a system to control the
expression of multiple VHH variants. As proof-of-principle, we built the simplest
configuration for transcriptional control of multiple VHH variants, consisting of a dual-
input system in which the expression of two VHH variants is regulated by inducible promoters. Specifically, we designed a system in which the expression of the two VHH variants are independently controlled by the tetracycline repressor (TetR) (84) and erythromycin-dependent transrepressor (EKRAB), and can thus be independently regulated using the small-molecule inducers tetracycline (Tc) and erythromycin (Em), respectively (Fig. 7A). To build this system, we first transduced HEK293/GFP#1 cells for the expression of TetR and EKRAB and generated a stable cell line (HEK293/GFP2R) expressing GFP, TetR, and EKRAB. Induction of gene expression was characterized by transiently transfecting HEK293/GFP2R cells for the expression of iRFP under control of either the EKRAB or the TetR operator. Transfected cells were treated with the corresponding inducer and analyzed by flow cytometry to define the transgene expression levels as a function of inducer concentration (Supplementary Fig. 4). The expression of VHH variants in the dual-input system regulated by EKRAB or TetR is expected to be comparable to that of iRFP under the same conditions.

To test whether the extent of target protein localization to an extracytosolic compartment can be modulated by controlling the target degradation rate after induction of subcellular localization, we explored the use of a $\text{VHH}_{\text{Loc}}$ to first induce target subcellular localization followed by expression of a $\text{VHH}_{\text{Deg}}$ to control target degradation rate (Fig. 7A). Specifically, we implemented the dual-input system by transiently transfecting HEK293/GFP2R cells for the expression of $\text{VHH}_{\text{MOM}}$ under control of the Tc-inducible operator and the expression of $\text{VHH}_{\text{ODC}}$ under control of the Em-inducible operator. Transfected cells were first treated with Tc to induce expression of $\text{VHH}_{\text{MOM}}$. The resulting sample presenting localization of GFP to the mitochondria (Fig. 7B, left)
was cultured in the absence of Tc to discontinue expression of VHH_{MOM} and evaluate the residence time of GFP in the mitochondria (Fig. 7B, top right). A sample of cells cultured in the absence of Tc was also exposed to Em to induce expression of VHH_{ODC} and evaluate whether VHH_{ODC}-mediated degradation results in depletion of mitochondrial GFP (Fig. 7B, bottom right). Confocal microscopy analyses of mitochondria-localized GFP fluorescence revealed that cells not exposed to Em and thus not expressing VHH_{ODC} present minimal decrease in mitochondria-localized GFP fluorescence compared to cells analyzed at the end of the Tc induction period. Induction of VHH_{ODC} via cell treatment with Em, on the other hand, resulted in 87% decrease in mitochondria-localized GFP fluorescence (Fig. 7C). These results demonstrate the residence time of a target protein localized in a subcellular compartment can be modulated by controlling proteasome-mediated degradation of the target protein.

To test whether the extent of target protein localization to distinct extracytosolic compartments can by modulated by controlling the expression level of the corresponding VHH_{Loc} variants, we monitored GFP signal in two subcellular compartments (mitochondria and nucleus) upon modulation of the expression level of two VHH_{Loc} variants (VHH_{MOM} and VHH_{NLS}). Specifically, we used the dual-input system to induce expression of VHH_{MOM} under the control of the Em-inducible operator and VHH_{NLS} under the control of the Tc-inducible operator. Cells were treated with Em and Tc, separately or in combination, at concentrations expected to result in linear changes in target gene expression as estimated from iRFP induction analyses (Supplementary Fig. 4). Localization of GFP to the mitochondria and nuclei was assessed using confocal microscopy. Cell treatment with Em resulted in an increase in mitochondria-localized
GFP fluorescence to a 7.9-fold maximum compared to untreated cells and did not affect localization of GFP to the nucleus (Fig. 8A). Cell treatment with Tc resulted in an increase in nucleus-localized GFP fluorescence to a 2.2-fold maximum compared to untreated cells and did not affect localization of GFP to the mitochondria (Fig. 8B). Cells exposed to Em and Tc displayed GFP localization to both the nucleus and mitochondria (Fig. 8C). The extent of GFP colocalization with the nucleus and the mitochondria depended on the concentration of Em and Tc and thus on the expression level of the compartment-specific VHH\textsubscript{Loc} variants (Fig. 8D). These results demonstrate that localization of a target protein can be quantitatively tuned between different subcellular compartments by modulating the expression of the appropriate VHH\textsubscript{Loc} variants.

**Design of Genetic Toggle Switch for Spatial Control of GFP Output.**

To investigate whether the NanoLoc can be integrated within larger genetic networks to control the circuit components spatially, we built a genetic toggle switch circuit that regulates expression of two VHH\textsubscript{Loc} variants such that the state of the toggle switch dictates the expression of each VHH\textsubscript{Loc} variant and the resulting subcellular localization of the target protein. Toggle switch topologies in bacteria (85–87) and mammalian cells (69, 88, 89) are typically based on the function of two transcriptional repressors that mutually repress each other. To generate a toggle switch for spatial control of GFP localization between two subcellular compartments, we modified the classic toggle switch configuration (69, 85) to link the expression of two VHH\textsubscript{Loc} variants to that of the two repressors through an internal ribosome entry site (IRES) sequence (Fig. 9A). Specifically, HEK293/GFP\#1 cells were transiently transfected for the expression of
VHH\textsubscript{MOM} and EKRAB under the control of the Pristinimycin I (PI)-inducible operator and VHH\textsubscript{NLS} and PIPKRAB under the control of the Em-inducible operator. The same IRES was used to link expression of VHH\textsubscript{MOM} and VHH\textsubscript{NLS} to that of EKRAB and PIPKRAB to ensure equal ratios of expression. Transfected cells were treated with Em and PI and imaged by confocal microscopy to quantify GFP localization and verify that the state of the toggle switch determines the target’s subcellular localization.

To investigate the use of the spatial toggle switch to shift localization of GFP from the nucleus to the mitochondria, transfected HEK293/GFP\#1 cells expressing the VHH\textsubscript{Loc}-modified toggle switch were treated with pulses of Em and PI. Specifically, cells were treated with PI during transfection to initialize the toggle to mitochondrial localization by inducing expression of VHH\textsubscript{MOM} and PIPKRAB. Transfected cells were first treated with Em for 48 h to induce expression of VHH\textsubscript{NLS} (and EKRAB), resulting in repression of VHH\textsubscript{MOM} (and PIPKRAB), and then with PI for an additional 48 h to induce expression of VHH\textsubscript{MOM} (and PIPKRAB), resulting in repression of VHH\textsubscript{NLS} (and EKRAB). Control cells treated continuously with Em or PI to maximize expression of VHH\textsubscript{NLS} or VHH\textsubscript{MOM}, respectively, provided measurements of maximum localization of GFP to the mitochondria (PI treatment, Fig. 9B-D solid lines) or the nucleus (Em treatment, Fig. 9B-D, dashed lines) in the system. Imaging analyses at the end of the Em treatment (Fig. 9B, 48 h) showed low mitochondrial localization (left) and high nuclear localization (right) and the extent of localization to both the mitochondria and the nucleus was comparable to that observed in cells treated continuously with Em. After the switch to PI treatment (Fig. 9B, 96 h), cells displayed high mitochondrial localization (left) and low nuclear localization (right) and the extent of localization to both the mitochondria and the
nucleus was comparable to that observed in cells treated continuously with PI (Fig. 9B). These results indicate that GFP localization is switched from a state of predominantly nucleus-localized GFP to a state of predominantly mitochondria-localized GFP by switching from expression of VHH$_{\text{NLS}}$ to expression of VHH$_{\text{MOM}}$.

To demonstrate reversible switching of the toggle, we tested the opposite transition from mitochondria-localized GFP to nucleus-localized GFP. Cells were transiently transfected for expression of the spatial toggle switch in the presence of Em to initialize the toggle to nuclear localization by inducing expression of VHH$_{\text{NLS}}$ and EKRAB. Transfected cells were first treated with PI for 48 h to induce expression of VHH$_{\text{MOM}}$ (and PIPKRAB), resulting in repression of VHH$_{\text{NLS}}$ (and EKRAB), and then with Em for an additional 48 h to induce expression of VHH$_{\text{NLS}}$ (and EKRAB), resulting in repression of VHH$_{\text{MOM}}$ (and PIPKRAB). Confocal microscopy analyses of GFP subcellular localization at the end of PI treatment (Fig. 9C, 48 h) showed high mitochondrial localization (left) and low nuclear localization (right). Similar to the previous experiment, the extent of localization to both the mitochondria and the nucleus was comparable to that observed in cells treated continuously with PI. After the switch to Em treatment (Fig. 9C, 96 h), cells displayed low mitochondrial localization (left) and high nuclear localization (right) at levels corresponding to those observed in cells treated continuously with Em (Fig. 9C), indicating a shift from nuclear to mitochondrial localization upon switch of the expression of VHH$_{\text{Loc}}$.

These results (Figs. 9B and 9C), taken together, indicate that localization of the target protein can be reversibly switched between the mitochondria and the nucleus by switching the state of the spatial toggle switch circuit.
In addition to reversible switching, another key feature of the toggle switch topology is bistability of the system (69, 85). Bistability is denoted by the presence of two path-dependent stable output states for given inputs (i.e., a fixed set of inducer concentrations) (90). To demonstrate bistability of the spatial toggle switch, we treated cells with two different inducers to generate two different initial conditions and then removed the inducers to subject cells exposed to different initial conditions to a common input condition. We monitored GFP localization to determine whether the outputs associated with each initial condition remained stable. Specifically, HEK293/GFP#1 cells were exposed to a pulse of either PI or EM during transient transfection for expression of the spatial toggle switch, and then incubated without inducer. Confocal microscopy analyses of GFP subcellular localization 48 h and 96 h after removal of PI (Fig. 9D, white bars) showed high mitochondrial localization (left) and low nuclear localization (right). The extent of localization to both the mitochondria and the nucleus was again comparable to that observed in cells induced with PI and cultured continuously in the presence of PI for 96 h (Fig. 9D, solid line). Imaging analyses of cells treated with a pulse of Em (Fig. 9D, striped bars) displayed low mitochondrial localization (left) and high nuclear localization (right) at levels comparable to those observed in cells treated continuously with Em (dashed line). The GFP localization levels achieved upon cell exposure to a pulse of inducer were maintained for 96 h post-induction, indicating the spatial toggle switch displays bistable localization to either the mitochondria or the nucleus depending on the initial conditions of the circuit.

These results indicate that the NanoLoc platform can be integrated with a genetic circuit to exert spatial control over the outputs through appropriate design of the circuit.
topology, thus providing an additional mode for control for the design of synthetic gene networks.

**DISCUSSION**

Strategies for user-defined control of protein subcellular localization allow investigating the role of protein localization in a variety of cellular function (15, 17, 24, 91), including mechanisms that mediate the cellular response to external stimuli (17–19, 22). An array of intrinsic localization signals that dictate the subcellular address of proteins have been characterized (13). Fusion of localization signals to target proteins enables protein relocation to the desired subcellular compartment (51), but requires genetic manipulation of the target protein, which may affect the protein’s native function independently of localization (52). Most importantly, direct fusion of target proteins to localization signals does not allow modulating the extent of target localization to the desired subcellular compartment. Interacting protein domains have also been employed to engineer inducible localization systems in which the target and a compartment-specific protein are fused to interacting partners (40, 41, 50, 56–61). While providing an opportunity for tunable and reversible control of protein localization, these systems depend largely on the choice of binding partner and often require extensive development and re-engineering for customization to other target proteins. Regulating target localization through the use of target-specific recognition molecules functionalized with localization signals enables spatial control of the resulting complex without the need for target manipulation (63, 64, 92, 93). Nanobody-mediated localization has enabled a number of fundamental studies, including investigations of the role of fascin
and cortactin in invadopodium formation (64) and the role of survivin localization during mitosis (63). These methods, however, do not provide tunable control over the extent of target localization and typically result in irreversible localization. The potential of these strategies for the development of a universal, plug-and-play technology for reversible control of target localization that can be adapted to any cellular protein and used to direct localization to different subcellular compartments remains uncharacterized.

In this study, we addressed the need for a technology for controlling localization of cellular proteins with multi-compartment specificity, tunable control over the localized target concentration, and dynamic control over the target residence time. We developed a modular system (NanoLoc) based on nanobodies, which are the smallest antigen recognition domain and bind to cellular targets with high specificity and selectivity (94–96), and a comprehensive series of localization signal sequences, which when fused to the target-specific nanobody determine localization of the nanobody-target protein complex. Nanobodies are readily obtained from immunized Camelids (97–102) and can be evolved (103–108) or engineered (109) to target a seemingly unlimited number of sequences using display technologies commonly employed to evolve mammalian antibodies. The small size and stability of nanobodies allows for easy expression (110, 111) and excellent tissue penetration (112). The NanoLoc platform can be adapted to achieve control of a target protein of interest through the use of a target-specific nanobody. We thus envision that this platform could be customized to target virtually any cellular protein sequence, as well as protein conformation (113–115) and post-translational modification (113, 116). While possibly not generalizable to some classes of target proteins for which stability and function is typically contingent upon interaction
with cellular structures such as membranes, this approach is expected to present great potential for controlling the function of soluble proteins. It is also important to note that, the extent of localization of the target protein using the NanoLoc platform may vary depending on the cellular context due to cell type specific variability (117).

Customization of the nanobody-based platform developed in this study with respect to the localization determining sequence allows user-defined control of target localization to potentially any subcellular compartment (13). The choice of localization signal also determines the target residence time within the signal-specific compartment. The molecular mechanisms determining the target residence time within the signal-specific compartments remains uncharacterized. Understanding the response kinetics of the VHH_Loc variants would inform the design of NanoLoc systems with superior control over the kinetics of target subcellular localization. The reversible nature of the VHH_Loc-induced perturbation allows minimizing irreversible downstream effects and exposing phenotypic changes that depend on the duration of the perturbation. Such localization-based perturbation (40) may thus prove useful in elucidating mechanisms regulating cell signaling (118, 119) and viral infections (92, 120, 121). The NanoLoc platform could also be used to investigate the effect of aberrant localization of disease-related proteins (39, 122, 123). Finally, the NanoLoc platform could provide a useful tool to control localization of multiple cellular proteins simultaneously; such applications would require optimization of the target-specific nanobody expression levels to account for differences in nanobody-target binding affinities.

We demonstrated that our nanobody-based system can achieve spatial and temporal control over a target protein by combining nanobody-mediated localization
(NanoLoc) and degradation (NanoDeg) technologies with transcriptional regulation. Small-molecule inducible promoters were used to drive orthogonal expression of VHH_{Loc} and VHH_{Deg} variants in a dual-input system, thereby tuning the duration of localization and the localized concentration of a target protein in multiple subcellular compartments. The NanoLoc system could also be expanded to localize multiple proteins to a single subcellular compartment by combining distinct VHH_{Loc} variants customized to recognize multiple targets. Developing the NanoLoc platform to control multiple targets in a distinct cellular compartment could open the way to a variety of metabolic engineering applications as it provides a powerful approach to regulate metabolite fluxes by controlling the local concentration of key reaction components (44, 124).

Finally, we demonstrated the use of the GFP-specific NanoLoc as a modular unit for synthetic genetic circuits that allows spatial control of the circuit’s reporter protein. Synthetic mammalian gene networks are typically designed to regulate the concentration of a single reporter protein (125). By contrast, the NanoLoc enables regulation of both location and local concentration of the reporter protein, thereby broadening the cell engineering potential of synthetic gene networks. We integrated VHH_{Loc} variants within a transcriptional toggle switch configuration and demonstrated reversible localization of a target protein that depends on the state of the toggle switch. We anticipate that this strategy for spatial control of genetic circuit outputs will provide a useful method for orthogonal regulation of spatially constrained reactions using synthetic circuits that can reversibly locate a key reaction component (25) in response to the state of the genetic circuit.
In summary, the NanoLoc system provides an innovative technology for spatial and temporal control of protein concentration in mammalian cells that can be customized for controlling the localization of target cellular proteins and integrated within more complex transcription-based circuitries to diversify the functionality of synthetic gene circuits.

FIGURE LEGENDS

Figure 1 NanoLoc-mediated control of GFP subcellular localization. Representative confocal microscopy images of HEK293/GFP#1 cells transiently transfected for expression of VHH_{Loc} variants and analyzed 72 h post-transfection. Subcellular compartment (red, column 1); GFP (green, column 2); VHH (blue, anti-HA, column 3); colocalization of subcellular compartment and VHH shown in merged images (purple, column 4); colocalization of GFP and VHH shown in merged images (cyan, column 5); colocalization of subcellular compartment and GFP shown in merged images (yellow, column 6). Scale bars: 5 µm. Brightness and contrast levels were adjusted and images of cells treated the same were subjected to the same adjustment. Pseudo-coloring was applied to the subcellular compartment stain and VHH images for the plasma membrane and the nucleus.

Figure 2 Residence time of NanoLoc-mediated GFP subcellular localization. (A) Schematic representation of the NanoLoc platform (left). Expression of VHH_{Loc} is induced upon addition of erythromycin (Em) which displaces the erythromycin-independent transrepressor (EKRAB) from the erythromycin operator (ETR). EKRAB is expressed constitutively. Cells were treated with erythromycin for 16 h to induce
expression of VHH$_{\text{Loc}}$. Confocal microscopy analyses were initiated at the time of removal of Em (t=0) from the culturing medium (right). **(B)** Representative confocal microscopy images of HEK293/GFP2R cells transiently transfected for the expression of VHH$_{\text{Loc}}$ variants and induced with erythromycin (Em, 500 ng/mL) 8 h post-transfection. Time-course analyses were initiated at the time of Em removal (t = 0 h) and conducted every 24 h for 144 h. Scale bars: 5 µm. Brightness levels were adjusted and images of cells treated the same were subjected to the same adjustment.

**Figure 3** NanoLoc-mediated control of GFP subcellular localization upon expression of multiple VHH$_{\text{Loc}}$ variants. Representative confocal microscopy images of HEK293/GFP#1 cells transiently transfected for expression of **(A)** a single VHH$_{\text{Loc}}$ variant and **(B)** two VHH$_{\text{Loc}}$ variants using a 1:1 plasmid ratio. Samples were analyzed 72 h post-transfection. Scale bars: 5 µm. Brightness levels were adjusted and images of cells treated the same were subjected to the same adjustment.

**Figure 4** GFP mitochondrial localization as a function of VHH$_{\text{MOM}}$ and GFP expression level. **(A)** Mitochondria-localized and cytosolic GFP fluorescence of HEK293/GFP#1 cells transiently transfected with plasmid expressing VHH$_{\text{MOM}}$ (0 - 450 ng) and analyzed 72 h post-transfection by confocal microscopy. Mitochondria-localized GFP fluorescence intensity values were obtained by quantifying the GFP signal that co-localizes with the MitoTracker stain. Data are reported as mean ± s.e.m. (n = 3, p < 0.05, Student’s t-test, n.s. = not significant). Black dots represent biological replicates. **(B)** Mitochondria-localized and cytosolic GFP fluorescence of stable HEK293 cell lines...
presenting low (HEK293/GFP#1), intermediate (HEK293/GFP#2), and high (HEK293/GFP#3) GFP expression levels transiently transfected with plasmid expressing VHH\textsubscript{MOM} (450 ng). Mitochondria-localized GFP fluorescence intensity values were obtained by quantifying the GFP signal that co-localizes with the MitoTracker stain. Data are reported as mean ± s.e.m. (n = 3, p < 0.05, Student’s t-test). Black dots represent the biological replicates.

**Figure 5** NanoLoc mediated control of tTA function. GFP expression in HEK293 cells expressing GFP under the control of tTA (TRE.GFP) and either tTA-NLS or tTA-BC2T and VHH\textsubscript{BC2T}\textsubscript{NLS}. Relative GFP fluorescence values were obtained by normalizing GFP signal to iRFP signal to correct for differences in transfection efficiency. Data are reported as mean ± s.e.m. (n = 3, p < 0.01, Student’s t-test, n.s. = not significant). Black dots represent biological replicates.

**Figure 6** Modulation of mitochondria-localized GFP fluorescence via nanobody-mediated GFP degradation. (A-B) Confocal microscopy analyses of HEK293/GFP#1 cells transiently transfected for the expression of VHH\textsubscript{MOM} and VHH\textsubscript{ODC} using VHH\textsubscript{MOM}:VHH\textsubscript{ODC} plasmid mass ratios of 1:0, 1:0.5, 1:2, and 1:3. A filler plasmid lacking vhh was used to maintain constant total plasmid mass. Images were analyzed 72 h post-transfection. (A) Representative images of mitochondria-localized GFP fluorescence. Scale bars: 5 µm. Brightness levels were adjusted and images of cells treated the same were subjected to the same adjustment. (B) Average mitochondria-localized GFP fluorescence. Fluorescence intensity values were obtained by quantifying
the GFP signal that co-localizes with the MitoTracker stain. Data are reported as mean ± s.e.m. (n = 3, p < 0.005, Student’s t-test). Black dots represent biological replicates. (C-D) Confocal microscopy analyses of HEK293/GFP#1 cells transiently transfected with a plasmid expressing VHH_{MOM} and a plasmid expressing a VHH_{ODC} variant (VHH_{ODC(T15A)}, half-life 2.1 h; VHH_{ODC}, half-life 1.3 h; and VHH_{ODC(D12A)}, half-life 0.9 h) or lacking vhh in a 1:2 plasmid mass ratio and analyzed 72 h post-transfection. (C) Representative images of mitochondria-localized GFP fluorescence. Scale bars: 5 µm. Brightness levels were adjusted and images of cells treated the same were subjected to the same adjustment. (D) Average mitochondria-localized GFP fluorescence. Fluorescence intensity values were obtained by quantifying the GFP signal that co-localizes with the MitoTracker stain. Data are reported as mean ± s.e.m. (n = 3, p < 0.005, Student’s t-test). Black dots represent biological replicates.

**Figure 7** A dual-input expression system for temporal control of GFP localization. (A) Schematic representation of the dual-input system to control expression of two VHH variants. The tetracycline repressor (TetR) and erythromycin-dependent transrepressor (EKRAB) are constitutively expressed from a single promoter. Expression of VHH_{MOM} is repressed by TetR binding to the tetracycline operator (TO) and induced with tetracycline (Tc). Expression of VHH_{ODC} is repressed by EKRAB binding to the erythromycin operator (ETR) and induced with erythromycin (Em). (B-C) Confocal microscopy analyses of HEK293/GFP2R cells transiently transfected with the dual expression systems described in A and cultured in the presence of Tc (50ng/mL) for the first 16 h and then in the presence or absence of Em (500 ng/mL) for an additional 48 h.
(B) Representative images of cells at 16 h (Tc treatment, left) and 64 h (right. Em free media, top; Em supplemented media, bottom). Scale bars: 5 µm. Brightness levels were adjusted and images of cells treated the same were subjected to the same adjustment.

(C) Average mitochondria-localized GFP fluorescence of cells analyzed at 16 h (left of dashed line) and 64 h (right of dashed line) post-transfection. Fluorescence intensity values were obtained by quantifying the GFP signal that co-localizes with the MitoTracker stain. Data are reported as mean ± s.e.m. (n = 3, p < 0.01, Student’s t-test). Black dots represent biological replicates.

Figure 8 Modulation of GFP localization to different subcellular compartment using a dual-input nanobody expression system. (A-D) Mitochondria- and nucleus-localized GFP fluorescence in HEK293/GFP2R cells transiently transfected for the expression of VHH\textsubscript{MOM} under control of the Em-inducible operator and VHH\textsubscript{NLS} under control of the Tc-inducible operator, treated with the inducers (Em and Tc) 16 h post-transfection and analyzed after 48 h of induction. (A) GFP fluorescence localized with the mitochondria (white bars) and with the nucleus (striped bars) in transfected cells cultured in the presence of Em (0-500 ng/mL) and in the absence of Tc. Relative fluorescence values were obtained by normalizing the GFP signal that co-localizes with the VHH\textsubscript{Loc}-specific compartment to the co-localized GFP signal of untreated samples. (B) GFP fluorescence localized with the mitochondria (white bars) and with the nucleus (striped bars) in transfected cells cultured in the presence Tc (0-500 ng/mL) and in the absence of Em. Relative fluorescence values were obtained as described in A. (C) Representative images of cells treated with Tc and Em. Scale bars: 5 µm. Brightness
levels were adjusted and images of cells treated the same were subjected to the same adjustment. (D) GFP fluorescence localized with the mitochondria (white bars) and with the nucleus (striped bars) in transfected cells cultured in the presence of both Em and Tc. Relative fluorescence values were obtained as described in A. All data are reported as mean ± s.e.m. (n = 3, p < 0.05, Student’s t-test). Black dots represent biological replicates.

Figure 9 A synthetic toggle switch to control GFP subcellular localization. (A) Schematic representation of the spatial toggle switch. Expression of VHH_{MOM} is linked to that of EKRAB and expression of VHH_{NLS} is linked to that of PIPKRAB. Expression of VHH_{MOM} and EKRAB are repressed by PIPKRAB binding to the pristinamycin operator (PIR) and induced by pristinamycin I (PI). Expression of VHH_{NLS} and PIPKRAB are repressed by EKRAB binding to the erythromycin operator (ETR) and induced by erythromycin (Em) (B-D) Mitochondria- and nucleus-localized GFP fluorescence of HEK293/GFP#1 cells transiently transfected with plasmids for expression of the spatial toggle switch described in A and analyzed by confocal microscopy. Relative fluorescence values were obtained by normalizing the GFP signal that co-localizes with the VHH_{Loc}-specific compartment to the co-localized GFP signal of untreated samples. (B) Relative localized GFP fluorescence of transfected cells cultured in the presence of PI during transfection to initialize cells to VHH_{MOM} and PIPKRAB expression, then treated with Em (500 ng/mL) for the first 48 h, and with PI (500 ng/mL) for the other 48 h. Cells were analyzed at the end of Em treatment (48 h) and at the end of the PI treatment (96 h). Control cells were treated continuously with PI (solid line) and Em
(dashed line). (C) Relative localized GFP fluorescence of transfected cells cultured in the presence of Em during transfection to initialize cells to VHH\textsubscript{NLS} and EKRAB expression, then treated with PI (500 ng/mL) for the first 48 h, and with Em (500 ng/mL) for other 48 h. Cells were analyzed at the end of PI treatment (48 h) and at the end of Em treatment (96 h). Control cells were treated continuously with PI (solid line) and Em (dashed line). (D) Relative localized GFP fluorescence of transfected cells cultured in the presence of PI (white bars) or of Em (striped bars) during transfection (16 h) and then in inducer-free medium (untreated, UT) for 96 h. Cells were analyzed 48 h and 96 h after removal of the inducer. Control cells were treated continuously with PI (solid line) and Em (dashed line). All data are reported as mean ± s.e.m. (n = 3, p < 0.05, Student’s t-test). Black dots represent biological replicates.

SUPPLEMENTARY DATA

The Supplementary Information is available on SYNBIO Online: Supplementary Figures 1-4 supporting the results in the main text, Supplementary Table 1 reporting the localization tags, Supplementary Table 2 reporting plasmids, and Supplementary Table 3 reporting the oligonucleotides used in this study (PDF).

AUTHOR CONTRIBUTIONS

BJ and LS designed the project. BJ and BB constructed plasmids and cell lines. BJ, BB and ZW performed experiments. BJ and BB analyzed the data. SML contributed to the image analysis. BJ and LS wrote the article. BB, BJ, and LS revised the manuscript.
CONFLICT OF INTEREST

The authors declare no competing financial interest.

ACKNOWLEDGEMENTS AND FUNDING

We thank A. B. Utama and staff of the Shared Equipment Authority at Rice University for assistance with imaging. This work was supported by the National Science Foundation (MCB-1615562 and CBET 1805317 and 1930149) and the Welch Foundation (C-1824).
REFERENCES

1. Berg, J., Tymoczko, J. and Stryer, L. (2002) Biochemistry, 5. Auflage.
2. Bauer, N.C., Doetsch, P.W. and Corbett, A.H. (2015) Mechanisms Regulating Protein Localization. *Traffic*, **16**, 1039–1061.
3. Coulon, A., Chow, C.C., Singer, R.H. and Larson, D.R. (2013) Eukaryotic transcriptional dynamics: From single molecules to cell populations. *Nat. Rev. Genet.*, **14**, 572–584.
4. Weake, V.M. and Workman, J.L. (2010) Inducible gene expression: Diverse regulatory mechanisms. *Nat. Rev. Genet.*, 10.1038/nrg2781.
5. Lambert, S.A., Jolma, A., Campitelli, L.F., Das, P.K., Yin, Y., Albu, M., Chen, X., Taipale, J., Hughes, T.R. and Weirauch, M.T. (2018) The Human Transcription Factors. *Cell*, 10.1016/j.cell.2018.01.029.
6. Lelli, K.M., Slattery, M. and Mann, R.S. (2012) Disentangling the Many Layers of Eukaryotic Transcriptional Regulation. *Annu. Rev. Genet.*, 10.1146/annurev-genet-110711-155437.
7. Hochstrasser, M. (1995) Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. *Curr. Opin. Cell Biol.*, 10.1016/0955-0674(95)80031-X.
8. Seglen, P.O. and Bohley, P. (1992) Autophagy and other vacuolar protein degradation mechanisms. *Experientia*, 10.1007/BF01923509.
9. Goldberg, A.L. (2003) Protein degradation and protection against misfolded or damaged proteins. *Nature*, 10.1038/nature02263.
10. Liu, H., Urbé, S. and Clague, M.J. (2012) Selective protein degradation in cell signalling. *Semin. Cell Dev. Biol.*, **23**, 509–514.
11. Kraft, C., Peter, M. and Hofmann, K. (2010) Selective autophagy: Ubiquitin-mediated recognition and beyond. *Nat. Cell Biol.*, 10.1038/ncb0910-836.

12. Varshavsky, A. (2011) The N-end rule pathway and regulation by proteolysis. *Protein Sci.*, 10.1002/pro.666.

13. Negi, S., Pandey, S., Srinivasan, S.M., Mohammed, A. and Guda, C. (2015) LocSigDB: A database of protein localization signals. *Database*, 10.1093/database/bav003.

14. Chan, P., Lovrić, J. and Warwicker, J. (2006) Subcellular pH and predicted pH-dependent features of proteins. *Proteomics*, 10.1002/pmic.200500534.

15. Sweetlove, L.J. and Fernie, A.R. (2013) The Spatial Organization of Metabolism Within the Plant Cell. *Annu. Rev. Plant Biol.*, 10.1146/annurev-arplant-050312-120233.

16. Jakobson, C.M., Tullman-Ercek, D. and Mangan, N.M. (2018) Spatially organizing biochemistry: Choosing a strategy to translate synthetic biology to the factory. *Sci. Rep.*, 10.1038/s41598-018-26399-0.

17. Kakkar, P. and Singh, B.K. (2007) Mitochondria: A hub of redox activities and cellular distress control. *Mol. Cell. Biochem.*, 10.1007/s11010-007-9520-8.

18. Good, M.C., Zalatan, J.G. and Lim, W.A. (2011) Scaffold proteins: Hubs for controlling the flow of cellular information. *Science (80-. ).*, 10.1126/science.1198701.

19. Morrison, D.K. and Davis, R.J. (2003) Regulation of MAP Kinase Signaling Modules by Scaffold Proteins in Mammals. *Annu. Rev. Cell Dev. Biol.*, 10.1146/annurev.cellbio.19.111401.091942.

20. Konopka, M.C., Shkel, I.A., Cayley, S., Record, M.T. and Weisshaar, J.C. (2006) Crowding and confinement effects on protein diffusion in vivo. *J. Bacteriol.*,
10.1128/JB.01982-05.

21. Ólafsson, G. and Thorpe, P.H. (2016) Synthetic physical interactions map kinetochore-checkpoint activation regions. *G3 Genes, Genomes, Genet.*, 6, 2531–2542.

22. Takano, A., Usui, I., Haruta, T., Kawahara, J., Uno, T., Iwata, M. and Kobayashi, M. (2001) Mammalian Target of Rapamycin Pathway Regulates Insulin Signaling via Subcellular Redistribution of Insulin Receptor Substrate 1 and Integrates Nutritional Signals and Metabolic Signals of Insulin. *Mol. Cell. Biol.*, 10.1128/mcb.21.15.5050-5062.2001.

23. Kamatkar, S., Radha, V., Nambirajan, S., Reddy, R.S. and Swarup, G. (1996) Two splice variants of a tyrosine phosphatase differ in substrate specificity, DNA binding, and subcellular location. *J. Biol. Chem.*, 10.1074/jbc.271.43.26755.

24. Jagnandan, D., Sessa, W.C. and Fulton, D. (2005) Intracellular location regulates calcium-calmodulin-dependent activation of organelle-restricted eNOS. *Am. J. Physiol. - Cell Physiol.*, 10.1152/ajpcell.00162.2005.

25. Hao, N., Budnik, B.A., Gunawardena, J. and O'Shea, E.K. (2013) Tunable signal processing through modular control of transcription factor translocation. *Science (80-. ).*, 10.1126/science.1227299.

26. Jeong, S.Y. and Seol, D.W. (2008) The role of mitochondria in apoptosis. *J. Biochem. Mol. Biol.*

27. Grant, B.D. and Donaldson, J.G. (2009) Pathways and mechanisms of endocytic recycling. *Nat. Rev. Mol. Cell Biol.*, 10.1038/nrm2755.

28. Ryu, J. and Park, S.H. (2015) Simple synthetic protein scaffolds can create
adjustable artificial MAPK circuits in yeast and mammalian cells. *Sci. Signal.*, 10.1126/scisignal.aab3397.

29. Agapakis,C.M., Boyle,P.M. and Silver,P.A. (2012) Natural strategies for the spatial optimization of metabolism in synthetic biology. *Nat. Chem. Biol.*, 10.1038/nchembio.975.

30. Chatterjee,G., Dalchau,N., Muscat,R.A., Phillips,A. and Seelig,G. (2017) A spatially localized architecture for fast and modular DNA computing. *Nat. Nanotechnol.*, 10.1038/nnano.2017.127.

31. Yogurtcu,O.N. and Johnson,M.E. (2018) Cytosolic proteins can exploit membrane localization to trigger functional assembly. *PLoS Comput. Biol.*, 10.1371/journal.pcbi.1006031.

32. Myhrvold,C., Polka,J.K. and Silver,P.A. (2016) Synthetic Lipid-Containing Scaffolds Enhance Production by Colocalizing Enzymes. *ACS Synth. Biol.*, 10.1021/acssynbio.6b00141.

33. Bassell,G.J. and Kelic,S. (2004) Binding proteins for mRNA localization and local translation, and their dysfunction in genetic neurological disease. *Curr. Opin. Neurobiol.*, 10.1016/j.conb.2004.08.010.

34. Wang,W., Van Niekerk,E., Willis,D.E. and Twiss,J.L. (2007) RNA transport and localized protein synthesis in neurological disorders and neural repair. *Dev. Neurobiol.*, 10.1002/dneu.20511.

35. Kowall,N.W. and Kosik,K.S. (1987) Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer’s disease. *Ann. Neurol.*, 10.1002/ana.410220514.
36. Calvo, S., Jain, M., Xie, X., Sheth, S.A., Chang, B., Goldberger, O.A., Spinazzola, A., Zeviani, M., Carr, S.A. and Mootha, V.K. (2006) Systematic identification of human mitochondrial disease genes through integrative genomics. *Nat. Genet.*, 10.1038/ng1776.

37. Lee, D.S., Park, J., Kay, K.A., Christakis, N.A., Oltvai, Z.N. and Barabási, A.L. (2008) The implications of human metabolic network topology for disease comorbidity. *Proc. Natl. Acad. Sci. U. S. A.*, 10.1073/pnas.0802208105.

38. Wang, X. and Li, S. (2014) Protein mislocalization: Mechanisms, functions and clinical applications in cancer. *Biochim. Biophys. Acta - Rev. Cancer*, 10.1016/j.bbcancer.2014.03.006.

39. Hung, M.C. and Link, W. (2011) Protein localization in disease and therapy. *J. Cell Sci.*, 10.1242/jcs.089110.

40. Robinson, M.S., Sahlender, D.A. and Foster, S.D. (2010) Rapid Inactivation of Proteins by Rapamycin-Induced Rerouting to Mitochondria. *Dev. Cell*, 18, 324–331.

41. Umeda, N., Ueno, T., Pohlmeier, C., Nagano, T. and Inoue, T. (2011) A photocleavable rapamycin conjugate for spatiotemporal control of small GTPase activity. *J. Am. Chem. Soc.*, 10.1021/ja108258d.

42. Toby, G.G. and Golemis, E.A. (2001) Targeting proteins to specific cellular compartments to optimize physiological activity. *Methods Enzymol.*, 332, 77–87.

43. Yadav, V.G., De Mey, M., Giaw Lim, C., Kumaran Ajikumar, P. and Stephanopoulos, G. (2012) The future of metabolic engineering and synthetic biology: Towards a systematic practice. *Metab. Eng.*, 14, 233–241.

44. Lee, H., DeLoache, W.C. and Dueber, J.E. (2012) Spatial organization of enzymes for
metabolic engineering. *Metab. Eng.*, 10.1016/j.ymben.2011.09.003.

45. Prelich,G. (2012) Gene overexpression: Uses, mechanisms, and interpretation. *Genetics*, 190, 841–854.

46. Blackstock,W.P. and Weir,M.P. (1999) Proteomics: Quantitative and physical mapping of cellular proteins. *Trends Biotechnol.*, 10.1016/S0167-7799(98)01245-1.

47. Kim,H. and Kim,J.S. (2014) A guide to genome engineering with programmable nucleases. *Nat. Rev. Genet.*, 15, 321–334.

48. Bashor,C.J., Horwitz,A.A., Peisajovich,S.G. and Lim,W.A. (2010) Rewiring Cells: Synthetic Biology as a Tool to Interrogate the Organizational Principles of Living Systems. *Annu. Rev. Biophys.*, 10.1146/annurev.biophys.050708.133652.

49. Olson,E.J. and Tabor,J.J. (2012) Post-translational tools expand the scope of synthetic biology. *Curr. Opin. Chem. Biol.*, 16, 300–306.

50. Harmansa,S., Alborelli,I., Bieli,D., Caussinus,E. and Affolter,M. (2017) A nanobody-based toolset to investigate the role of protein localization and dispersal in Drosophila. *Elife*, 6, 1–22.

51. Goedhart,J., Von Stetten,D., Noirclerc-Savoye,M., Lelimousin,M., Joosen,L., Hink,M.A., Van Weeren,L., Gadella,T.W.J. and Royant,A. (2012) Structure-guided evolution of cyan fluorescent proteins towards a quantum yield of 93%. *Nat. Commun.*, 10.1038/ncomms1738.

52. Campbell,A.E. and Bennett,D. (2016) Targeting protein function: The expanding toolkit for conditional disruption. *Biochem. J.*, 10.1042/BCJ20160240.

53. Hosein,R.E., Williams,S.A., Haye,K. and Gavin,R.H. (2003) Expression of GFP-Actin Leads to Failure of Nuclear Elongation and Cytokinesis in Tetrahymena
thermophila. *J. Eukaryot. Microbiol.*, 10.1111/j.1550-7408.2003.tb00261.x.

54. Nelson, M. and Silver, P. (1989) Context affects nuclear protein localization in *Saccharomyces cerevisiae*. *Mol. Cell. Biol.*, 10.1128/mcb.9.2.384.

55. Douglas, M.G., McCammon, M.T. and Vassarotti, A. (1986) Targeting proteins into mitochondria. *Microbiol. Rev.*

56. Putyrski, M. and Schultz, C. (2012) Protein translocation as a tool: The current rapamycin story. *FEBS Lett.*, 10.1016/j.febslet.2012.04.061.

57. Brown, K.A., Zou, Y., Shirvanyants, D., Zhang, J., Samanta, S., Mantravadi, P.K., Dokholyan, N. V. and Deiters, A. (2015) Light-cleavable rapamycin dimer as an optical trigger for protein dimerization. *Chem. Commun.*, 10.1039/c4cc09442e.

58. Geda, P., Patury, S., Ma, J., Bharucha, N., Dobry, C.J., Lawson, S.K., Gestwicki, J.E. and Kumar, A. (2008) A small molecule-directed approach to control protein localization and function. *Yeast*, 10.1002/yea.1610.

59. Toettcher, J.E., Gong, D., Lim, W.A. and Weiner, O.D. (2011) Light control of plasma membrane recruitment using the Phy-PIF system. *Methods Enzymol.*, 10.1016/B978-0-12-385075-100017-2.

60. Buckley, C.E., Moore, R.E., Reade, A., Goldberg, A.R., Weiner, O.D. and Clarke, J.D.W. (2016) Reversible Optogenetic Control of Subcellular Protein Localization in a Live Vertebrate Embryo. *Dev. Cell*, 10.1016/j.devcel.2015.12.011.

61. Adrian, M., Nijenhuis, W., Hoogstraaten, R.I., Willems, J. and Kapitein, L.C. (2017) A Phytochrome-Derived Photoswitch for Intracellular Transport. *ACS Synth. Biol.*, 10.1021/acssynbio.6b00333.

62. Van Audenhove, I., Van Impe, K., Ruano-Gallego, D., De Clercq, S., De Muynck, K.,
Vanloo, B., Verstraete, H., Fernández, L.Á. and Gettemans, J. (2013) Mapping cytoskeletal protein function in cells by means of nanobodies. *Cytoskeleton*, 10.1002/cm.21122.

63. Beghein, E., Van Audenhove, I., Zwaenepoel, O., Verhelle, A., De Ganck, A. and Gettemans, J. (2016) A new survivin tracer tracks, delocalizes and captures endogenous survivin at different subcellular locations and in distinct organelles. *Sci. Rep.*, 10.1038/srep31177.

64. Van Audenhove, I., Boucherie, C., Pieters, L., Zwaenepoel, O., Vanloo, B., Martens, E., Verbrugge, C., Hassanzadeh-Ghassabeh, G., Vandenkerckhove, J., Cornelissen, M., et al. (2014) Stratifying fascin and cortactin function in invadopodium formation using inhibitory nanobodies and targeted subcellular delocalization. *FASEB J.*, 10.1096/fj.13-242537.

65. Virant, D., Traenkle, B., Maier, J., Kaiser, P.D., Bodenhöfer, M., Schmees, C., Vojnovic, I., Pisak-Lukáts, B., Endesfelder, U. and Rothbauer, U. (2018) A peptide tag-specific nanobody enables high-quality labeling for dSTORM imaging. *Nat. Commun.*, 9, 1–14.

66. Zhao, W., Pferdehirt, L. and Segatori, L. (2018) Quantitatively Predictable Control of Cellular Protein Levels through Proteasomal Degradation. *ACS Synth. Biol.*, 7, 540–552.

67. Zhao, W., Bonem, M., McWhite, C., Silberg, J.J. and Segatori, L. (2014) Sensitive detection of proteasomal activation using the Deg-On mammalian synthetic gene circuit. *Nat. Commun.*, 5, 3612.

68. Weber, W., Fux, C., Daoud-El Baba, M., Keller, B., Weber, C.C., Kramer, B.P.,
Heinzen, C., Aubel, D., Bailey, J.E. and Fussenegger, M. (2002) Macrolide-based transgene control in mammalian cells and mice. *Nat. Biotechnol.*, **20**, 901–907.

69. Kramer, B.P., Viretta, A.U., Baba, M.D.E., Aubel, D., Weber, W. and Fussenegger, M. (2004) An engineered epigenetic transgene switch in mammalian cells. *Nat. Biotechnol.*, **22**, 867–870.

70. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) Fiji: An open-source platform for biological-image analysis. *Nat. Methods*, **9**, 676–682.

71. Caussinus, E., Kanca, O. and Affolter, M. (2012) Fluorescent fusion protein knockout mediated by anti-GFP nanobody. *Nat. Struct. Mol. Biol.*, **19**, 117–122.

72. Horie, C., Suzuki, H., Sakaguchi, M. and Mihara, K. (2002) Characterization of signal that directs C-tail-anchored proteins to mammalian mitochondrial outer membrane. *Mol. Biol. Cell*, **13**, 1615–1625.

73. Anderie, I., Schulz, I. and Schmid, A. (2007) Characterization of the C-terminal ER membrane anchor of PTP1B. *Exp. Cell Res.*, **313**, 3189–3197.

74. Brocard, C. and Hartig, A. (2006) Peroxisome targeting signal 1: Is it really a simple tripeptide? *Biochim. Biophys. Acta - Mol. Cell Res.*, **1763**, 1565–1573.

75. Clift, D., McEwan, W.A., Labzin, L.I., Konieczny, V., Mogessie, B., James, L.C. and Schuh, M. (2017) A Method for the Acute and Rapid Degradation of Endogenous Proteins. *Cell*, **171**, 1692-1706.e18.

76. Kalderon, D., Roberts, B.L., Richardson, W.D. and Smith, A.E. (1984) A short amino acid sequence able to specify nuclear location. *Cell*, **39**, 499–509.

77. Newman, L.E., Schiavon, C. and Kahn, R.A. (2016) Plasmids for variable expression
of proteins targeted to the mitochondrial matrix or intermembrane space. *Cell. Logist.*, 6, 1–11.

78. Angelici, B., Mailand, E., Haefliger, B. and Benenson, Y. (2016) Synthetic Biology Platform for Sensing and Integrating Endogenous Transcriptional Inputs in Mammalian Cells. *Cell Rep.*, 16, 2525–37.

79. Gossen, M. and Bujard, H. (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc. Natl. Acad. Sci. U. S. A.*, 89, 5547–5551.

80. Strathdee, C.A., McLeod, M.R. and Hall, J.R. (1999) Efficient control of tetracycline-responsive gene expression from an autoregulated bi-directional expression vector. *Gene*, 229, 21–29.

81. Yoshida, Y. and Hamada, H. (1997) Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal. *Biochem. Biophys. Res. Commun.*, 230, 426–430.

82. Matsuzawa, S. -i., Cuddy, M., Fukushima, T. and Reed, J.C. (2005) Method for targeting protein destruction by using a ubiquitin-independent, proteasome-mediated degradation pathway. *Proc. Natl. Acad. Sci.*, 102, 14982–14987.

83. Li, X., Zhao, X., Fang, Y., Jiang, X., Duong, T., Fan, C., Huang, C. and Kain, S.R. (1998) Generation of Destabilized Green Fluorescent Protein as a Transcription Reporter *. 273*, 34970–34975.

84. Hillen, W. and Berens, C. (1994) Mechanisms underlying expression of Tn10 encoded tetracycline resistance. *Annu. Rev. Microbiol.*, 48, 345–69.

85. Gardner, T.S., Cantor, C.R. and Collins, J.J. (2000) Construction of a genetic toggle
switch in Escherichia coli. *Nature*, **403**, 339–342.

86. Sadeghpour, M., Veliz-Cuba, A., Orosz, G., Josić, K. and Bennett, M. R. Bistability and oscillations in co-repressive synthetic microbial consortia. 10.1007/s40484-017-0100-y.

87. Kobayashi, H., Kaern, M., Araki, M., Chung, K., Gardner, T. S., Cantor, C. R. and Collins, J. J. (2004) Programmable cells: Interfacing natural and engineered gene networks. *Proc. Natl. Acad. Sci.*, **101**, 8414–8419.

88. Greber, D., El-Baba, M. D. and Fussenegger, M. (2008) Intronically encoded siRNAs improve dynamic range of mammalian gene regulation systems and toggle switch. *Nucleic Acids Res.*, **36**, e101.

89. Müller, K., Engesser, R., Metzger, S., Schulz, S., Kämpf, M. M., Busacker, M., Steinberg, T., Tomakidi, P., Ehrbar, M., Nagy, F., et al. (2013) A red/far-red light-responsive bi-stable toggle switch to control gene expression in mammalian cells. *Nucleic Acids Res.*, **41**.

90. Del Vecchio, D. and Sontag, E. D. (2007) Dynamics and control of synthetic biomolecular networks. In *Proceedings of the American Control Conference*. pp. 1577–1588.

91. Berry, L. K., Ólafsson, G., Ledesma-Fernández, E. and Thorpe, P. H. (2016) Synthetic protein interactions reveal a functional map of the cell. *Elife*, **5**, 1–17.

92. Cattaneo, A. and Biocca, S. (1999) The selection of intracellular antibodies. *Trends Biotechnol.*, 10.1016/S0167-7799(98)01268-2.

93. Alessandra Vigano, M., Bieli, D., Schaefer, J. V., Jakob, R. P., Matsuda, S., Maier, T., Plückthun, A. and Affolter, M. (2018) DARPins recognize mTFP1 as novel reagents

https://mc.manuscriptcentral.com/synbio
for in vitro and in vivo protein manipulations. *Biol. Open*, 10.1242/bio.036749.

94. Decanniere,K., Desmyter,A., Lauwereys,M., Ghahroudi,M.A., Muyldermans,S. and Wyns,L. (1999) A single-domain antibody fragment in complex with RNase A: Non-canonical loop structures and nanomolar affinity using two CDR loops. *Structure*, 10.1016/S0969-2126(99)80049-5.

95. Desmyter,A., Decanniere,K., Muyldermans,S. and Wyns,L. (2001) Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-domain Antibody. *J. Biol. Chem.*, 10.1074/jbc.M102107200.

96. Beghein,E. and Gettemans,J. (2017) Nanobody technology: A versatile toolkit for microscopic imaging, protein-protein interaction analysis, and protein function exploration. *Front. Immunol.*, 10.3389/fimmu.2017.00771.

97. Monegal,A., Ami,D., Martinelli,C., Huang,H., Aliprandi,M., Capasso,P., Francavilla,C., Ossolegno,G. and De Marco,A. (2009) Immunological applications of single-domain llama recombinant antibodies isolated from a naïve library. *Protein Eng. Des. Sel.*, 22, 273–280.

98. Pardon,E., Laeremans,T., Triest,S., Rasmussen,S.G.F., Wohlkönig,A., Ruf,A., Muyldermans,S., Hol,W.G.J., Kobilka,B.K. and Steyaert,J. (2014) A general protocol for the generation of Nanobodies for structural biology. *Nat. Protoc.*, 9, 674–693.

99. Fu,X., Gao,X., He,S., Huang,D., Zhang,P., Wang,X., Zhang,S., Dang,R., Yin,S., Du,E., et al. (2013) Design and Selection of a Camelid Single-Chain Antibody Yeast Two-Hybrid Library Produced De Novo for the Cap Protein of Porcine Circovirus Type 2 (PCV2). *PLoS One*, 8.
100. Schut, M.H., Pepers, B.A., Klooster, R., van der Maarel, S.M., el Khatabi, M., Verrips, T., den Dunnen, J.T., van Ommen, G.J.B. and van Roon-Mom, W.M.C. (2015) Selection and characterization of llama single domain antibodies against N-terminal huntingtin. *Neurol. Sci.*, **36**, 429–434.

101. Ghahroudi, M.A., Desmyter, A., Wyns, L., Hamers, R. and Muyldermans, S. (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. *FEBS Lett.*, **414**, 521–526.

102. Van Der Linden, R., De Geus, B., Stok, W., Bos, W., Van Wassenaar, D., Verrips, T. and Frenken, L. (2000) Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of *Lama glama*. *J. Immunol. Methods*, 10.1016/S0022-1759(00)00188-5.

103. Sabir, J.S.M., Atef, A., El-Domyati, F.M., Edris, S., Hajrah, N., Alzohairy, A.M. and Bahieldin, A. (2014) Construction of naïve camelids VHH repertoire in phage display-based library. *Comptes Rendus - Biol.*, **337**, 244–249.

104. Moutel, S., Bery, N., Bernard, V., Keller, L., Lemesre, E., De Marco, A., Ligat, L., Rain, J.C., Favre, G., Olichon, A., et al. (2016) NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. *Elife*, **5**, 1–31.

105. Yan, J., Li, G., Hu, Y., Ou, W. and Wan, Y. (2014) Construction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications. *J. Transl. Med.*, **12**, 1–12.

106. Tanha, J., Dubuc, G., Hirama, T., Narang, S.A. and MacKenzie, C.R. (2002) Selection by phage display of llama conventional VH fragments with heavy chain antibody
VHH properties. *J. Immunol. Methods*, 10.1016/S0022-1759(02)00027-3.

107. Goldman, E.R., Andersen, G.P., Liu, J.L., Delehanty, J.B., Sherwood, L.J., Osborn, L.E., Cummins, L.B. and Hayhurst, A. (2006) Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. *Anal. Chem.*, 10.1021/ac0610053.

108. Dufner, P., Jermutus, L. and Minter, R.R. (2006) Harnessing phage and ribosome display for antibody optimisation. *Trends Biotechnol.*, 10.1016/j.tibtech.2006.09.004.

109. Wagner, H.J., Wehrle, S., Weiss, E., Cavallari, M. and Weber, W. (2018) A two-step approach for the design and generation of nanobodies. *Int. J. Mol. Sci.*, 10.3390/ijms19113444.

110. Van Der Linden, R.H.J.J., Frenken, L.G.J.J., De Geus, B., Harmsen, M.M., Ruuls, R.C., Stok, W., De Ron, L., Wilson, S., Davis, P. and Verrips, C.T. (1999) Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. *Biochim. Biophys. Acta - Protein Struct. Mol. Enzymol.*, **1431**, 37–46.

111. Arbabi-Ghahroudi, M., Tanha, J. and MacKenzie, R. (2005) Prokaryotic expression of antibodies. *Cancer Metastasis Rev.*, 10.1007/s10555-005-6193-1.

112. Peng, H.-P., Lee, K.H., Jian, J.-W. and Yang, A.-S. (2014) Origins of specificity and affinity in antibody–protein interactions. *Proc. Natl. Acad. Sci.*, 10.1073/pnas.1401131111.

113. Guilliams, T., El-Turk, F., Buell, A.K., O’Day, E.M., Aprile, F.A., Esbjörner, E.K., Vendruscolo, M., Cremades, N., Pardon, E., Wyns, L., et al. (2013) Nanobodies
raised against monomeric α-synuclein distinguish between fibrils at different maturation stages. *J. Mol. Biol.*, **425**, 2397–2411.

114. Domanska, K., Vanderhaegen, S., Srinivasan, V., Pardon, E., Dupeux, F., Marquez, J. A., Giorgetti, S., Stoppini, M., Wyns, L., Bellotti, V., *et al.* (2011) Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic 2-microglobulin variant. *Proc. Natl. Acad. Sci.*, 10.1073/pnas.1008560108.

115. Rasmussen, S. G. F., Choi, H. J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D. M., Thian, F. S., Kobilka, T. S., *et al.* (2011) Structure of a nanobody-stabilized active state of the β2 adrenoceptor. *Nature*, 10.1038/nature09648.

116. Nguyen, V. K., Hamers, R., Wyns, L. and Muyldermans, S. (2000) Camel heavy-chain antibodies: Diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. *EMBO J.*, **19**, 921–930.

117. Qin, J. Y., Zhang, L., Clift, K. L., Hulur, I., Xiang, A. P., Ren, B. Z. and Lahn, B. T. (2010) Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. *PLoS One*, **5**, 3–6.

118. Kaji, H., Canaff, L., Lebrun, J. J., Goltzman, D. and Hendy, G. N. (2001) Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type β signaling. *Proc. Natl. Acad. Sci. U. S. A.*, 10.1073/pnas.061358098.

119. Bikkavilli, R. K., Feigin, M. E. and Malbon, C. C. (2008) p38 mitogen-activated protein kinase regulates canonical Wnt-β-catenin signaling by inactivation of GSK3β. *J. Cell Sci.*, 10.1242/jcs.032854.

120. Marasco, W. A., Haseltine, W. A. and Chen, S. (1993) Design, intracellular
expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. *Proc. Natl. Acad. Sci. U. S. A.*, 10.1073/pnas.90.16.7889.

121. Biocca, S., Ruberti, F., Tafani, M., Pierandrei-Amaldi, P. and Cattaneo, A. (1995) Redox state of single chain FV fragments targeted to the endoplasmic reticulum, cytosol and mitochondria. *Bio/Technology*, 10.1038/nbt1095-1110.

122. Moore, J.D. (2013) In the wrong place at the wrong time: Does cyclin mislocalization drive oncogenic transformation? *Nat. Rev. Cancer*, 10.1038/nrc3468.

123. Zempel, H. and Mandelkow, E. (2014) Lost after translation: Missorting of Tau protein and consequences for Alzheimer disease. *Trends Neurosci.*, 10.1016/j.tins.2014.08.004.

124. Dueber, J.E., Wu, G.C., Malmirchegini, G.R., Moon, T.S., Petzold, C.J., Ullal, A. V., Prather, K.L.J. and Keasling, J.D. (2009) Synthetic protein scaffolds provide modular control over metabolic flux. *Nat. Biotechnol.*, 10.1038/nbt.1557.

125. Greber, D. and Fussenegger, M. (2007) Mammalian synthetic biology: Engineering of sophisticated gene networks. *J. Biotechnol.*, 10.1016/j.jbiotec.2007.05.014.
Figure 1 NanoLoc-mediated control of GFP subcellular localization. Representative confocal microscopy images of HEK293/GFP#1 cells transiently transfected for expression of VHH\textsubscript{Loc} variants and analyzed 72 h post-transfection. Subcellular compartment (red, column 1); GFP (green, column 2); VHH (blue, anti-HA, column 3); colocalization of subcellular compartment and VHH shown in merged images (purple, column 4); colocalization of GFP and VHH shown in merged images (cyan, column 5); colocalization of subcellular compartment and GFP shown in merged images (yellow, column 6). Scale bars: 5 µm. Brightness and contrast levels were adjusted and images of cells treated the same were subjected to the same adjustment. Pseudo-coloring was applied to the subcellular compartment stain and VHH images for the plasma membrane and the nucleus.
Figure 2 Residence time of NanoLoc-mediated GFP subcellular localization. (A) Schematic representation of the NanoLoc platform (left). Expression of VHH\textsubscript{Loc} is induced upon addition of erythromycin (Em) which displaces the erythromycin-dependent transrepressor (EKARAB) from the erythromycin operator (ETR). EKRAB is expressed constitutively. Cells were treated with erythromycin for 16 h to induce expression of VHH\textsubscript{Loc}. Confocal microscopy analyses were initiated at the time of removal of Em (t=0) from the culturing medium (right). (B) Representative confocal microscopy images of HEK293/GFP2R cells transiently transfected for the expression of VHH\textsubscript{Loc} variants and induced with erythromycin (Em, 500 ng/mL) 8 h post-transfection. Time-course analyses were initiated at the time of Em removal (t = 0 h) and conducted every 24 h for 144 h. Scale bars: 5 μm. Brightness levels were adjusted and images of cells treated the same were subjected to the same adjustment.
Figure 3 NanoLoc-mediated control of GFP subcellular localization upon expression of multiple VHH\textsubscript{LOC} variants. Representative confocal microscopy images of HEK293/GFP\#1 cells transiently transfected for expression of (A) a single VHH\textsubscript{LOC} variant and (B) two VHH\textsubscript{LOC} variants using a 1:1 plasmid ratio. Samples were analyzed 72 h post-transfection. Scale bars: 5 \(\mu\)m. Brightness levels were adjusted and images of cells treated the same were subjected to the same adjustment.
Figure 4. GFP mitochondrial localization as a function of VHH\textsubscript{MOM} and GFP expression level. (A) Mitochondria-localized and cytosolic GFP fluorescence of HEK293/GFP#1 cells transiently transfected with plasmid expressing VHH\textsubscript{MOM} (0 - 450 ng) and analyzed 72 h post-transfection by confocal microscopy. Mitochondria-localized GFP fluorescence intensity values were obtained by quantifying the GFP signal that co-localizes with the MitoTracker stain. Data are reported as mean ± s.e.m. (n = 3, \( p < 0.05 \), Student’s t-test, n.s. = not significant). Black dots represent biological replicates. (B) Mitochondria-localized and cytosolic GFP fluorescence of stable HEK293 cell lines presenting low (HEK293/GFP#1), intermediate (HEK293/GFP#2), and high (HEK293/GFP#3) GFP expression levels transiently transfected with plasmid expressing VHH\textsubscript{MOM} (450 ng). Mitochondria-localized GFP fluorescence intensity values were obtained by quantifying the GFP signal that co-localizes with the MitoTracker stain. Data are reported as mean ± s.e.m. (n = 3, \( p < 0.05 \), Student’s t-test). Black dots represent the biological replicates.
Figure 5 NanoLoc mediated control of tTA function. GFP expression in HEK293 cells expressing GFP under the control of tTA (TRE.GFP) and either tTA-NLS or tTA-BC2T and VHHNLSBC2T. Relative GFP fluorescence values were obtained by normalizing GFP signal to iRFP signal to correct for differences in transfection efficiency. Data are reported as mean ± s.e.m. (n = 3, p < 0.01, Student’s t-test, n.s. = not significant). Black dots represent biological replicates.
Figure 6 Modulation of mitochondria-localized GFP fluorescence via nanobody-mediated GFP degradation. (A-B) Confocal microscopy analyses of HEK293/GFP#1 cells transiently transfected for the expression of VHH\textsubscript{MOM} and VHH\textsubscript{ODC} using VHH\textsubscript{MOM}:VHH\textsubscript{ODC} plasmid mass ratios of 1:0, 1:0.5, 1:2, and 1:3. A filler plasmid lacking vhh was used to maintain constant total plasmid mass. Images were analyzed 72 h post-transfection. (A) Representative images of mitochondria-localized GFP fluorescence. Scale bars: 5 µm. Brightness levels were adjusted and images of cells treated the same were subjected to the same adjustment. (B) Average mitochondria-localized GFP fluorescence. Fluorescence intensity values were obtained by quantifying the GFP signal that co-localizes with the MitoTracker stain. Data are reported as mean ± s.e.m. (n = 3, p < 0.005, Student’s t-test). Black dots represent biological replicates. (C-D) Confocal microscopy analyses of HEK293/GFP#1 cells transiently transfected with a plasmid expressing VHH\textsubscript{MOM} and a plasmid expressing a VHH\textsubscript{ODC} variant (VHH\textsubscript{ODC(T15A)}, half-life 2.1 h; VHH\textsubscript{ODC}, half-life 1.3 h; and VHH\textsubscript{ODC(D12A)}, half-life 0.9 h) or lacking vhh in a 1:2 plasmid mass ratio and analyzed 72 h post-transfection. (C) Representative images of mitochondria-localized GFP fluorescence. Scale bars: 5 µm.
Brightness levels were adjusted and images of cells treated the same were subjected to the same adjustment. (D) Average mitochondria-localized GFP fluorescence. Fluorescence intensity values were obtained by quantifying the GFP signal that co-localizes with the MitoTracker stain. Data are reported as mean ± s.e.m. (n = 3, p < 0.005, Student’s t-test). Black dots represent biological replicates.
Figure 7 A dual-input expression system for temporal control of GFP localization. (A) Schematic representation of the dual-input system to control expression of two VHH variants. The tetracycline repressor (TetR) and erythromycin-dependent transrepressor (EKRAB) are constitutively expressed from a single promoter. Expression of VHAMOM is repressed by TetR binding to the tetracycline operator (TO) and induced with tetracycline (Tc). Expression of VHHODC is repressed by EKRAB binding to the erythromycin operator (ETR) and induced with erythromycin (Em). (B-C) Confocal microscopy analyses of HEK293/GFP2R cells transiently transfected with the dual expression systems described in A and cultured in the presence of Tc (50ng/mL) for the first 16 h and then in the presence or absence of Em (500 ng/mL) for an additional 48 h. (B) Representative images of cells at 16 h (Tc treatment, left) and 64 h (right. Em free media, top; Em supplemented media, bottom). Scale bars: 5 µm. Brightness levels were adjusted and images of cells treated the same were subjected to the same adjustment. (C) Average mitochondria-localized GFP fluorescence of cells analyzed at 16 h (left of dashed line) and 64 h (right of dashed line) post-transfection. Fluorescence intensity values were obtained by quantifying the GFP signal that co-localizes with the...
MitoTracker stain. Data are reported as mean ± s.e.m. (n = 3, p < 0.01, Student’s t-test). Black dots represent biological replicates.
Figure 8 Modulation of GFP localization to different subcellular compartment using a dual-input nanobody expression system. (A-D) Mitochondria- and nucleus-localized GFP fluorescence in HEK293/GFP2R cells transiently transfected for the expression of VHH\textsubscript{MOM} under control of the Em-inducible operator and VHH\textsubscript{NLS} under control of the Tc-inducible operator, treated with the inducers (Em and Tc) 16 h post-transfection and analyzed after 48 h of induction. (A) GFP fluorescence localized with the mitochondria (white bars) and with the nucleus (striped bars) in transfected cells cultured in the presence of Em (0-500 ng/mL) and in the absence of Tc. Relative fluorescence values were obtained by normalizing the GFP signal that co-localizes with the VHH\textsubscript{Loc}-specific compartment to the co-localized GFP signal of untreated samples. (B) GFP fluorescence localized with the mitochondria (white bars) and with the nucleus (striped bars) in transfected cells cultured in the presence Tc (0-500 ng/mL) and in the absence of Em. Relative fluorescence values were obtained as described in A. (C) Representative images of cells treated with Tc and Em. Scale bars: 5 µm. Brightness levels were adjusted and images of cells treated the same were subjected to the same adjustment. (D) GFP fluorescence localized with the mitochondria (white bars) and with the nucleus (striped...
bars) in transfected cells cultured in the presence of both Em and Tc. Relative fluorescence values were obtained as described in A. All data are reported as mean ± s.e.m. (n = 3, p < 0.05, Student’s t-test). Black dots represent biological replicates.
Figure 9. A synthetic toggle switch to control GFP subcellular localization. (A) Schematic representation of the spatial toggle switch. Expression of VHH_{MOM} is linked to that of EKRAB and expression of VHH_{NLS} is linked to that of PIPKRAB. Expression of VHH_{MOM} and EKRAB are repressed by PIPKRAB binding to the pristinamycin operator (PIR) and induced by pristinamycin I (PI). Expression of VHH_{NLS} and PIPKRAB are repressed by EKRAB binding to the erythromycin operator (ETR) and induced by erythromycin (Em) (B-D) Mitochondria- and nucleus-localized GFP fluorescence of HEK293/GFP#1 cells transiently transfected with plasmids for expression of the spatial toggle switch described in A and analyzed by confocal microscopy. Relative fluorescence values were obtained by normalizing the GFP signal that co-localizes with the VHH_{Loc}-specific compartment to the co-localized GFP signal of untreated samples. (B) Relative localized GFP fluorescence of transfected cells cultured in the presence of PI during transfection to initialize cells to VHH_{MOM} and PIPKRAB expression, then treated with Em (500 ng/mL) for the first 48 h, and with PI (500 ng/mL) for the other 48 h. Cells were analyzed at the end of Em treatment (48 h) and at the end of the PI treatment (96 h). Control
cells were treated continuously with PI (solid line) and Em (dashed line). (C) Relative localized GFP fluorescence of transfected cells cultured in the presence of Em during transfection to initialize cells to VHH_{NLS} and EKRAB expression, then treated with PI (500 ng/mL) for the first 48 h, and with Em (500 ng/mL) for other 48 h. Cells were analyzed at the end of PI treatment (48 h) and at the end of Em treatment (96 h). Control cells were treated continuously with PI (solid line) and Em (dashed line). (D) Relative localized GFP fluorescence of transfected cells cultured in the presence of PI (white bars) or of Em (striped bars) during transfection (16 h) and then in inducer-free medium (untreated, UT) for 96 h. Cells were analyzed 48 h and 96 h after removal of the inducer. Control cells were treated continuously with PI (solid line) and Em (dashed line). All data are reported as mean ± s.e.m. (n = 3, p < 0.05, Student’s t-test). Black dots represent biological replicates.